Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis

Journal of Clinical Pharmacology

Volumn 47, Issue 7, 2007, Pages 850-859

  Czock, David ^a,d   Rasche, Franz Maximilian ^a,d   Carius, Alexander ^a,d   Glander, Petra ^a,d   Budde, Klemens ^a,d   Bauer, Steffen ^b,d   Keller, Frieder ^a,d   Von Müller, Lutz ^c,d  

^a Department of Nephrology ^*

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Enteric coated mycophenolate; IgA nephropathy; Mycophenolate mofetil; Pharmacodynamics; Pharmacokinetics

Indexed keywords

INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PRODRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENTERIC COATED TABLET; ENZYME ACTIVITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; MALE; STEADY STATE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; KIDNEY FAILURE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

AREA UNDER CURVE; CROSS-OVER STUDIES; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MYCOPHENOLIC ACID; PRODRUGS; RENAL INSUFFICIENCY; TABLETS, ENTERIC-COATED; THERAPEUTIC EQUIVALENCY;

EID: 34548051575     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007301624     Document Type: Article

References (25)

1. 1. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219-2228. (Pubitemid 41697285)
2. 2. Rasche FM, Keller F, von Müller L, Sailer LK, Karges W, Czock D. Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephropathy. J Nephrol. 2006;19:465-472. (Pubitemid 44823202)
3. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34: 429-455.
4. 4. Budde K, Glander P, Diekmann F, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother. 2004;5:1333-1345. (Pubitemid 38885793)
5. Budde K, Glander P, Mai I, et al. Mycophenolate mofetil and enteric-coated mycophenolate sodium have similar pharmacokinetic and pharmacodynamic profiles in stable renal allograft recipients. J Am Soc Nephrol. 2002;13:367A.
6. 6. Ams W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Ti-ansplant. 2005;19:199-206. (Pubitemid 40424890)
7. 7. Tedesco-Silva H, Bastien MC, Choi L, et al. Mycophenolic acid metabolite profile in renal transplant patients receiving entericcoated mycophenolate sodium or mycophenolate mofetil. Transplant Proc. 2005;37:852-855. (Pubitemid 40590723)
8. van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17:871-880.
9. 9. Cattaneo D, Merlini S, Zenoni S, et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant. 2005;5: 2937-2944. (Pubitemid 43923955)
10. 10. Neumann I, Haidinger M, Jager H, et al. Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared to renal transplant recipients. J Am Soc Nephrol. 2003; 14:721-727. (Pubitemid 36246016)
11. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987-994.
12. 12. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62:1060-1067. (Pubitemid 35316738)
13. 13. Gonzalez-Roncero FM, Gentil MA, Brunet M, et al. Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. Transplant Proc. 2005;37:3749-3751. (Pubitemid 43015154)
14. 14. MacPhee IA, Spreafico S, Bewick M, et al. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney Int. 2000;57:1164-1168. (Pubitemid 30434805)
15. 15. Johnson HJ, Swan SK, Heim-Duthoy KL, Nicholls AJ, Tsina I, Tarnowski T. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin Pharmacol Ther. 1998;63:512-518. (Pubitemid 28277272)
16. 16. Vethe NT, Mandla R, Line PD, Midtvedt K, Hartmann A, Bergan S. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment. Scand J Clin Lab Invest. 2006;66:31-44. (Pubitemid 43220758)
17. 17. Glander P, Hambach P, Braun KP, et al. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther. 2003;41:470-476. (Pubitemid 37258865)
18. 18. Glander P, Braun KP, Hambach P, et al. Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin Biochem. 2001;34:543-549. (Pubitemid 34014847)
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
20. 20. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol. 1996;36:315-324. (Pubitemid 26125953)
21. 21. Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44:61-98. (Pubitemid 40096038)
22. 22. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68:261-266. (Pubitemid 29360288)
23. 23. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokineticpharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672-683. (Pubitemid 29011387)
24. 24. Oellerich M, Shipkova M, Schutz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications of therapeutic drug monitoring. Ther Drug Monit. 2000;22:20-26. (Pubitemid 30083090)
25. 25. Jain J, Almquist SJ, Heiser AD, et al. Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. J Pharmacol Exp Ther. 2002;302:1272-1277. (Pubitemid 34920252)